Literature DB >> 15369754

Serum hyaluronan and hyaluronidase: very early markers of toxic liver injury.

Joseph George1, Robert Stern.   

Abstract

BACKGROUND: Dimethylnitrosamine (DMN), a potent hepatotoxin, administered to rats, provides a convenient model for toxic liver injury. Indicators of early liver injury are important clinically, for surveillance, for screening new drugs that are potentially hepatotoxic and for identifying drugs that protect against liver injury. Both cirrhosis and wound healing culminate in deposition of fibrous connective tissue and scarring. Increased hyaluronan (HA) occurs in the earliest stage of wound healing. Hyaluronidase, the enzyme that degrades hyaluronan, is also elevated whenever rapid turnover of hyaluronan occurs. We test the hypothesis that elevated levels of circulating hyaluronan and hyaluronidase could provide indicators of very early liver damage.
METHODS: Dimethylnitrosamine was administered to adult male albino rats by intraperitoneal injections for 7 consecutive days.
RESULTS: Increased serum hyaluronan levels observed on day 2 reached a maximum on day 4. Hyaluronidase was elevated on the first day and reached a maximum on day 2 that was 30-times control levels. Hyaluronan-specific staining in liver sections was maximal on day 7, occurring predominantly in portal triads and in sinusoidal spaces. Individual hepatocytes were slightly enlarged and contained intracellular hyaluronan, which was not evident in control sections. Though circulating hyaluronan levels had decreased after day 4, continued hyaluronan staining persisted in liver sections through day 21. Conventional indicators of liver injury, such as serum aminotransferase enzymes, did not reach a peak until day 7. Conventional gross and histopathological changes, including severe centrilobular congestion and hemorrhagic necrosis, were observed only after day 7. Both hyaluronan and hyaluronidase are indicators of very early liver damage in the dimethylnitrosamine-treated rat, occurring well before conventional indicators appear, or before overt histopathologic changes of liver damage can be seen. However, levels are increased only transiently, indicating that serial assays are necessary.
CONCLUSIONS: Measures of circulating hyaluronidase activity may be used to assess liver damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369754     DOI: 10.1016/j.cccn.2004.05.018

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  14 in total

1.  The effects of sorafenib on liver regeneration in a model of partial hepatectomy.

Authors:  Peter C Kurniali; Katie O'Gara; Xiaofei Wang; Li Juan Wang; Ponnandai Somasundar; Vincent Falanga; N Joseph Espat; Steven C Katz
Journal:  J Surg Res       Date:  2012-03-29       Impact factor: 2.192

Review 2.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  Effect of anticoagulants on the plasma hyaluronidase activities.

Authors:  R Sharma; Y H Mahadeswaraswamy; K Harish Kumar; S Devaraja; K Kemparaju; B S Vishwanath; K S Girish
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Low molecular weight hyaluronan activates cytosolic phospholipase A2α and eicosanoid production in monocytes and macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Michael Eberlein; Asuncion Martinez-Anton; Yueqin Liu; Sara Alsaaty; Hai-Yan Qi; Carolea Logun; Maureen Horton; James H Shelhamer
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

5.  High levels of hyaluronan in idiopathic pulmonary arterial hypertension.

Authors:  Metin Aytekin; Suzy A A Comhair; Carol de la Motte; Sudip K Bandyopadhyay; Carol F Farver; Vincent C Hascall; Serpil C Erzurum; Raed A Dweik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-05       Impact factor: 5.464

6.  Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation.

Authors:  Kosho Yamanouchi; Hongchao Zhou; Namita Roy-Chowdhury; Frank Macaluso; Liping Liu; Toshiyuki Yamamoto; Govardhana Rao Yannam; Charles Enke; Timothy D Solberg; Anthony B Adelson; Jeffrey L Platt; Ira J Fox; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

7.  Mesenchymal stem cell-conditioned medium prevents radiation-induced liver injury by inhibiting inflammation and protecting sinusoidal endothelial cells.

Authors:  Yi-Xing Chen; Zhao-Chong Zeng; Jing Sun; Hai-Ying Zeng; Yan- Huang; Zhen-Yu Zhang
Journal:  J Radiat Res       Date:  2015-06-11       Impact factor: 2.724

8.  Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia.

Authors:  Korakot Nganvongpanit; Akanit Itthiarbha; Siriwan Ong-Chai; Prachya Kongtawelert
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

Review 9.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

10.  Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.

Authors:  Yasuhiro Matsue; Mikihiro Tsutsumi; Nobuhiko Hayashi; Takashi Saito; Mutsumi Tsuchishima; Nobuyuki Toshikuni; Tomiyasu Arisawa; Joseph George
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.